Abpro, a biotechnology company focused on therapeutics, diagnostics, and research, agreed to go public via a SPAC merger with Atlantic Coastal Acquisition II, a special purpose acquisition corporation, in a $725m deal. “This is a milestone for Abpro, and we look forward to working with Atlantic Coastal and its team. The proceeds we expect to raise in connection with this transaction will help accelerate the advancement of our pipeline toward clinical trials and provide the foundation for ongoing development of novel immunotherapies to help patients,” Ian Chan, Abpro CEO and Co-Founder.